High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy

Purpose: To investigate the prognostic value of survivin expression in pretreatment specimens from patients with anal cancer treated with concurrent 5-FU and mitomycin C-based chemoradiation (CRT).

Material and methods:
Purpose: To investigate the prognostic value of survivin expression in pretreatment specimens from patients with anal cancer treated with concurrent 5-FU and mitomycin C-based chemoradiation (CRT).

Material and methods: Immunohistochemical staining for survivin was performed in pretreatment biopsies of 62 patients with anal carcinoma. Survivin expression was correlated with clinical and histopathological characteristics as well as local failure free- (LFFS), distant metastases free- (DMFS), cancer specific- (CSS), and overall survival (OS).

Results: Survivin staining intensity was weak in 10%, intermediate in 48% and intense in 42% of the patients. No association between survivin expression and clinicopathologic factors (tumor stage, age and HIV status) could be shown. In univariate analysis, the level of survivin staining was significantly correlated with DMFS (low survivin vs. high survivin: 94% vs. 74%, p=0.04). T-stage, N-stage and the tumor grading were significantly associated with OS and CSS and with DMFS and LFFS, respectively. In multivariate analysis, survivin was confirmed as independent prognostic parameter for DMFS (RR, 0.04; p=0.02) and for OS (RR, 0.27; p=0.04).

Conclusion: Our results demonstrated that the level of pretreatment survivin is correlated with the clinical outcome in patients with anal carcinoma treated with concurrent CRT. Further studies are warranted to elucidate the complex role of survivin for the oncologic treatment and to exploit the protein as a therapeutic target in combined modality treatment of anal cancer.
show moreshow less

Download full text files

Export metadata

  • Export Bibtex
  • Export RIS

Additional Services

    Share in Twitter Search Google Scholar
Metadaten
Author:Ingeborg Fraunholz, Claus Rödel, Luitpold Distel, Margret Rave-Fränk, Daniela Kohler, Stefan Falk, Franz Rödel
URN:urn:nbn:de:hebis:30:3-252301
DOI:http://dx.doi.org/doi:10.1186/1748-717X-7-88
ISSN:1748-717X
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=22697293
Parent Title (English):Radiation oncology
Publisher:BioMed Central
Place of publication:London
Document Type:Article
Language:English
Date of Publication (online):2012/06/14
Date of first Publication:2012/06/14
Publishing Institution:Univ.-Bibliothek Frankfurt am Main
Release Date:2012/09/02
Tag:Anal cancer; Concurrent chemoradiotherapy; Molecular marker; Survivin
Volume:7
Issue:7:88
Pagenumber:7
First Page:1
Last Page:7
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 2.0

$Rev: 11761 $